Swine Bibliography Centre
|
Support that keeps you updated for FREE  |
Bulletin No. 18 - Spring 2004
VirologyPMWS-PCV2-PCVD-PDNS
BLANCHARD P, MAHE D, CARIOLET R, KERANFLEC'H A, BAUDOUARD MA, ALBINA E, JESTIN A
Protection contre la maladie d'amaigrissement du porcelet (MAP) par vaccins ? ADN et protéines recombinantes. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins.
Journées Recherche Porcine, 36, 2004, 345-352 - Vaccine, 21, 2003, 4565-4575
Two vaccination trials based on the use of two major proteins (ORF1-encoded replication protein and ORF2-encoded capsid protein) of PCV2 were carried out. The approach consisted in associating a DNA vaccine and a subunit vaccine. The DNA vaccine was made of a plasmid containing ORF1 and/or ORF2 and a plasmid encoding GM-CSF (granulocyte macrophage colony stimulating factor) which serves as natural adjuvant. The subunit vaccine contained replication and/or capsid proteins and an adjuvant (Montanide). In the first protocol, pigs received a first injection of DNA vaccine followed 2 weeks later by a second injection of DNA vaccine and subunit vaccine. Weight gain, and the presence of fever and lesions were used as parameters to assess the efficacy of vaccination after challenge. ORF2-encoded capsid protein showed more immunogenicity compared to ORF1-encoded replication protein and provided a good level of protection against PCV2 infection. In the second protocol the efficacy of the DNA vaccine was compared to that of the subunit vaccine. The subunit vaccine induced a better protection than the DNA vaccine. Besides, PCV2 replication appeared to vary according to the type of vaccine, suggesting that the type of immune response may have an influence on the expression of PMWS.
